CytoDyn, Inc. (CYDY)
|Address:1111 Main Street
Vancouver, WA 98660
|Phone||360 980 8524|
|Fiscal Year||June - May|
|Reporting Currency||US Dollars|
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.
Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19).
It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients.
The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient.
The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
|Dr. Scott A. Kelly||Chairman, Chief Medical Officer and Head of Business Development|
|Dr. Nader Z. Pourhassan||Chief Executive Officer, President and Director|
|Dr. Nitya G. Ray||Chief Technology Officer and Head of Process Sciences, Manufacturing and Supply Chain|
|Michael D. Mulholland CPA, CPA||Senior Vice President of Finance|
|Antonio Migliarese||Chief Financial Officer and Treasurer|
|Dr. Christopher P. Recknor M.D.||Chief Operating Officer and Head of Clinical Development|
|Arian Colachis J.D.||Senior Vice President, General Counsel and Corporate Secretary|
|Dr. Brendan P. Rae||Senior Vice President of Business Development|
|George Bitar||Head of Quality and Executive Director|
|Dr. Kush Dhody||Senior Vice President of Clinical Operations|
Latest SEC Filings
|Jul 22, 2021||8-K||Current report|
|Jul 20, 2021||PREC14A||Preliminary proxy statements, contested solicitations|
|Jul 12, 2021||3||Initial statement of beneficial ownership of securities|
|Jul 9, 2021||8-K||Current report|
|Jul 7, 2021||DFAN14A||Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material|
|Jul 6, 2021||8-K||Current report|
|Jul 2, 2021||SC 13D/A||General statement of acquisition of beneficial ownership|
|Jul 1, 2021||DFAN14A||Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material|
|Jun 21, 2021||8-K||Current report|
|Jun 15, 2021||8-K||Current report|
|View All SEC filings|